Philogen S.p.A.

Equities

PHIL

IT0005373789

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-28 am EDT			5-day change	1st Jan Change
20.5 ^EUR	+3.02%		+14.53%	+10.81%

05:58pm	Mib in the red; BPER and Intesa resist declines	AN
May. 24	Mib down but Iveco and Pirelli soar	AN

Philogen S p A : Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio

July 02, 2021 at 01:33 pm EDT

Press Releases

Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio

Apr 27, 2021

Il Consiglio di Amministrazione approva il progetto di bilancio di esercizio e il bilancio consolidato al 31 dicembre 2020 (Price Sensitive)

Last Press Releases

Jul20212

Philogen Announces R&D Program Update

Jun202129

Deposito del Verbale dell'Assemblea degli Azionisti (Price sensitive)

Attachments

Original document
Permalink

Disclaimer

Philogen S.p.A. published this content on 02 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2021 17:32:22 UTC.

Latest news about Philogen S.p.A.

Mib in the red; BPER and Intesa resist declines	11:58am	AN
Mib down but Iveco and Pirelli soar	May. 24	AN
Philogen, NFP and liquidity drop in first quarter	May. 07	AN
Indices up; Italy, industrial sales down	Apr. 12	AN
Transcript : Philogen S.p.A., 2023 Earnings Call, Apr 03, 2024	Apr. 03
Philogen reduces loss in 2023; NFP remains positive	Mar. 27	AN
Philogen S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Mib re-emerges in green; Saipem resumes rally	Mar. 07	AN
Futures await lists in red	Feb. 27	AN
Europeans down; Sogefi flies in Piazza Affari.	Feb. 26	AN
Philogen S.p.A. Provides Update on Pre-Planned Interim Analysis of the Phase III FIBROSARC Trial Investigating Onfekafusp Alfa in Patients with First-Line Advanced or Metastatic Soft Tissue Sarcoma	Feb. 20	CI
Mib in the red at 31,600; TIM still on top	Feb. 19	AN
European indexes down; TIM tops Mib	Feb. 19	AN
Futures bullish; PMI data coming in.	Jan. 24	AN
Mib gives ground; Saipem resists declines	Jan. 23	AN
Mib loses 30,000 points; MPS shines	Jan. 17	AN
Mib falls below 30,400; Amplifon tops	Jan. 08	AN
Piazza Affari down slightly; banks on the Mib do well	Jan. 08	AN
Philogen S.P.A. Announces Receipt of the Good Manufacturing Practice Certificate for Its New Production Facility in Rosia (Siena, Italy) by Competent Authorities	Dec. 05	CI
Cucinelli on Mib in December; Philogen, d'Amico and SAES on Mid	Nov. 23	AN
Philogen, net financial position falls in third quarter	Nov. 08	AN
Philogen has purchased 3,300 shares of its own common stock	23-10-23	AN
Transcript : Philogen S.p.A. - Special Call	23-10-18
Philogen purchased 10,400 shares of its own common stock	23-10-17	AN
Philogen S.P.A. and Sun Pharmaceutical Industries Limited Announces Positive Results from the Phase III Pivotal Trial in Patients with Locally Advanced Fully Ressectable Melanoma	23-10-16	CI

Chart Philogen S.p.A.

Duration

Period

More charts

Company Profile

Philogen SpA is an Italy-based company, operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It has three anti-cancer antibody derivatives, produced with an in-house industrial process, into Phase I/II clinical studies. The majority of its technologies and products are based on high-affinity human monoclonal antibody fragments. Philogen SpA developed a patented technology, Iterative Colony Filter Screening, for the isolation of monoclonal antibodies, which requires neither immunization nor phage display. The Company's subsidiaries are Philotec, Philomed and Philochem. Philogen SpA is headquartered in Siena, Italy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-07 - Chemical Biology Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Philogen S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.9 EUR

Average target price

23.5 EUR

Spread / Average Target

+18.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHILOGEN S.P.A.	+10.81%	871M
VERTEX PHARMACEUTICALS INCORPORATED	+9.82%	118B
REGENERON PHARMACEUTICALS, INC.	+9.99%	106B
BIONTECH SE	-11.41%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.46%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.66%	14.03B
SAREPTA THERAPEUTICS, INC.	+16.59%	11.67B

Bio Therapeutic Drugs